Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Why AstraZeneca’s Olaparib Setback Could Be A Bigger Deal Than It Is

This article was originally published in The Pink Sheet Daily

Executive Summary

Investors don’t have enormous expectations for olaparib in the small subset of ovarian cancer patients AstraZeneca was targeting for accelerated approval, but the negative FDA advisory committee review comes at a pivotal time for the company.

You may also be interested in...



BIO 2014 Tuesday Round-Up: AstraZeneca Looking Forward, Not Back

With Day 2 of the BIO convention in San Diego in full swing, major deals, academic partnerships and hot pipelines take center stage – as long as they can be discussed in the World Cup Lounge.

Darzalex Surpasses Stelara As J&J’s Best-Selling Drug

Sales of Stelara are expected to begin tapering off later this year when the first biosimilars launch in mid-2024 in Europe and later in the US.

With One Launch Under Way, SpringWorks Ramps Up For A Second

The company initiated a rolling submission with the US FDA for mirdametinib, a MEK inhibitor that is poised to be its second commercial product for a rare disease.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS077374

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel